Your browser doesn't support javascript.
loading
New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463.
Zhu, Yi; Doornebal, Ewald J; Pirtskhalava, Tamar; Giorgadze, Nino; Wentworth, Mark; Fuhrmann-Stroissnigg, Heike; Niedernhofer, Laura J; Robbins, Paul D; Tchkonia, Tamara; Kirkland, James L.
Afiliação
  • Zhu Y; Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, USA.
  • Doornebal EJ; Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, USA.
  • Pirtskhalava T; Faculty of Science and Engineering, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
  • Giorgadze N; Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, USA.
  • Wentworth M; Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, USA.
  • Fuhrmann-Stroissnigg H; Office of Research Regulatory Support, Mayo Clinic, Rochester, MN 55905, USA.
  • Niedernhofer LJ; Department of Molecular Medicine and the Center on Aging, The Scripps Research Institute, Jupiter, FL 33458, USA.
  • Robbins PD; Department of Molecular Medicine and the Center on Aging, The Scripps Research Institute, Jupiter, FL 33458, USA.
  • Tchkonia T; Department of Molecular Medicine and the Center on Aging, The Scripps Research Institute, Jupiter, FL 33458, USA.
  • Kirkland JL; Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, USA.
Aging (Albany NY) ; 9(3): 955-963, 2017 03 08.
Article em En | MEDLINE | ID: mdl-28273655
ABSTRACT
Senescent cells accumulate with aging and at sites of pathology in multiple chronic diseases. Senolytics are drugs that selectively promote apoptosis of senescent cells by temporarily disabling the pro-survival pathways that enable senescent cells to resist the pro-apoptotic, pro-inflammatory factors that they themselves secrete. Reducing senescent cell burden by genetic approaches or by administering senolytics delays or alleviates multiple age- and disease-related adverse phenotypes in preclinical models. Reported senolytics include dasatinib, quercetin, navitoclax (ABT263), and piperlongumine. Here we report that fisetin, a naturally-occurring flavone with low toxicity, and A1331852 and A1155463, selective BCL-XL inhibitors that may have less hematological toxicity than the less specific BCL-2 family inhibitor navitoclax, are senolytic. Fisetin selectively induces apoptosis in senescent but not proliferating human umbilical vein endothelial cells (HUVECs). It is not senolytic in senescent IMR90 cells, a human lung fibroblast strain, or primary human preadipocytes. A1331852 and A1155463 are senolytic in HUVECs and IMR90 cells, but not preadipocytes. These agents may be better candidates for eventual translation into clinical interventions than some existing senolytics, such as navitoclax, which is associated with hematological toxicity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Flavonoides / Senescência Celular / Proteína bcl-X / Antineoplásicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Flavonoides / Senescência Celular / Proteína bcl-X / Antineoplásicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article